Healthpeak Properties (NYSE:DOC) announces FY 2026 earnings guidance. Healthpeak Properties (NYSE:DOC - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 1.760-1.780 for the period, compared to the consensus EPS estimate of 1.770. Healthpeak Properties price performance. Shares of NYSE DOC opened at $19.63 on Wednesday. Healthpeak Properties has a fifty-two week low of $15.70 and a fifty-two week high of $22.95. The business has a 50 day moving average price of $19.82 and a two-hundred day moving average price of $19.16. The company has a quick ratio of 3.02, a current ratio of 3.02 and a debt-to-equity ratio of 1.06. The firm has a market cap of $13.53 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 2.41 and a beta of 1.01. Healthpeak Properties (NYSE:DOC - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The real estate investment trust reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.41). Healthpeak Properties had a return on equity of 4.25% and a net margin of 12.32%. The business had revenue of $820.89 million for the quarter, compared to analysts' expectations of $739.18 million. During the same quarter in the prior year, the firm earned $0.46 earnings per share. Healthpeak Properties's revenue for the quarter was up 16.3% compared to the same quarter last year. Sell-side analysts expect that Healthpeak Properties will post 1.77 earnings per share for the current fiscal year. Healthpeak Properties dividend announcement. The business also recently declared a monthly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Friday, December 18th will be given a dividend of $0.1017 per share. The ex-dividend date of this dividend is Friday, December 18th. This represents a $1.22 dividend on an annualized basis and a dividend yield of 6.2%. Healthpeak Properties's dividend payout ratio (DPR) is presently 225.93%. Analysts set new price targets. A number of analysts recently issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Healthpeak Properties from $21.00 to $24.00 and gave the stock an "outperform" rating in a research note on Monday, August 10th. Citigroup increased their price objective on shares of Healthpeak Properties from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Barclays reduced their price objective on shares of Healthpeak Properties from $24.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Tuesday, October 13th. Weiss Ratings lowered shares of Healthpeak Properties from a "hold (c+)" rating to a "hold (c)" rating in a report on Wednesday, September 16th. Finally, UBS Group dropped their target price on shares of Healthpeak Properties from $21.50 to $20.00 and set a "neutral" rating for the company in a research report on Tuesday, October 13th. Four research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Healthpeak Properties currently has an average rating of "Hold" and a consensus target price of $21.47. More Healthpeak Properties news. Here are the key news stories impacting Healthpeak Properties this week: * Healthpeak raised its full-year 2026 adjusted FFO guidance to $1.76-$1.78 per share, a range that brackets the $1.77 consensus estimate. Third-quarter adjusted FFO of $0.44 also topped the $0.43 estimate. * Operating activity was supportive: outpatient medical lease executions totaled 846,000 square feet, while senior housing growth and outpatient leasing helped drive results. Revenue rose 16.3% year over year. * Healthpeak is targeting a two- to three-year lease-up for lab properties tied to acquisitions that are about 41% occupied. Longer-term leasing could add income, but occupancy needs time to improve. * Adjusted FFO declined from $0.46 per share a year earlier, and reported GAAP EPS of $0.02 was well below the cited $0.43 consensus. Coverage also flagged refinancing risk, which may weigh on investor confidence amid ongoing financing needs. About Healthpeak Properties. Healthpeak Properties, Inc (NYSE:DOC) is a real estate investment trust that owns, operates and develops healthcare-related real estate in the United States. The company primarily serves healthcare providers, research organizations and senior-care operators through a portfolio of specialized properties. Its main activities include the ownership and leasing of outpatient medical office buildings, life science facilities and senior housing properties. These assets support services such as physician practices, ambulatory care, medical research and senior living. Receive News & Ratings for Healthpeak Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthpeak Properties and related companies with MarketBeat.com's FREE daily email newsletter.

Healthpeak Properties' shares rose about 0.4% to $19.56 after its third-quarter 2026 results, and are down roughly 10% over three months. The healthcare property owner reported adjusted funds from operations of $0.44 per share and raised full-year guidance again. Revenue rose about 16% to $820.9 million. Net income was $17.1 million, against a loss of $117.3 million a year earlier. Outpatient occupancy stood at 90.3%, and lab occupancy rose to 79.8%. Senior housing same-store net operating income grew 26%. Net debt to adjusted EBITDA held at 4.7x. Refinancing remains a risk. Healthpeak must refinance $650 million of senior notes that carry a coupon of about 3.5%, which could raise its interest costs.

Healthpeak raises 2026 guidance and bets $233 million on half-empty lab buildings. Healthpeak lifted its 2026 FFO guidance to $1.76-$1.78 a share and is buying four lab buildings that average 41% occupancy, while senior housing NOI at Janus Living jumped 25.9%. Healthpeak Properties is buying lab buildings that are mostly empty. The Denver-based health care REIT said it has acquired or agreed to acquire four life science buildings for about $233 million, with a blended occupancy of 41% across the three transactions. The purchases came alongside third-quarter results in which the company raised its full-year earnings guidance and its senior housing business grew same-store NOI 25.9%. The details are in Healthpeak's third-quarter 2026 earnings release, dated Nov. 2, 2026 and filed with the Securities and Exchange Commission. Healthpeak (NYSE: DOC) owns outpatient medical, lab and senior housing properties, and the quarter showed those three businesses heading in different directions. Healthpeak's bet on lab vacancy. Lab was the weakest of the three segments in the quarter. Same-store adjusted NOI in the segment fell 0.7% from a year earlier. The company said lab occupancy rose 130 basis points from the second quarter and 270 basis points since the end of 2025, and it signed 480,000 square feet of lab leases in the quarter, bringing the year-to-date total to 1.0 million. The acquisitions are an attempt to buy into that recovery at a low entry point. In San Diego's Sorrento Mesa submarket, Healthpeak acquired the senior construction loan on HQ Point and then the remaining equity interest, for a combined $105 million. The deal closed Sept. 30, 2026. HQ Point is a two-building, 236,000-square-foot lab campus that is 29% occupied. Two more purchases are under contract. One is a 145,000-square-foot building in South San Francisco for about $92 million, which is 49% occupied. The other is the remaining 51% interest in 100 Acorn Park Drive in Cambridge, Mass., a 129,000-square-foot building that is 53% occupied, for about $36 million. Healthpeak put the three deals' current cash yield at about 5% and said it expects a stabilized cash yield of about 9% to 10% once the space is leased. On its reading, the gap between today's yield and the stabilized target is the bet. If tenants fill the space, Healthpeak's returns rise toward that target. If lab demand stays weak, the company will be carrying more vacant space. Senior housing and outpatient medical results. Senior housing is now held through Janus Living (NYSE: JAN), the separately listed subsidiary in which Healthpeak owned 69% at Sept. 30, or 214.7 million shares and operating partnership units. Janus Living's third-quarter revenue rose 78% to $268 million and adjusted EBITDAre rose 101% to $105 million. Same-store adjusted NOI rose 25.9% and margins widened 360 basis points. Janus closed $1.75 billion of acquisitions in the quarter and about $370 million more through Oct. 30, with roughly $82 million under binding agreements. Outpatient medical, at 54.4% of same-store NOI the largest segment, grew same-store NOI 3.1%. Healthpeak executed 846,000 square feet of new and renewal outpatient leases in the quarter and 3.2 million square feet so far this year. In October it bought Westway One, a 146,000-square-foot Class A medical training facility in Houston, for $38 million. The building is fully leased to affiliates of HCA Healthcare with 11 years left on the lease, at an initial cap rate of about 7.4%. The release also restates the deal that reshaped the outpatient portfolio in July. Healthpeak contributed 86 outpatient medical properties, valued at about $2.1 billion, to a joint venture with affiliates of Brookfield Asset Management and received about $1.025 billion for selling a 49% interest. Earnings and the raised guidance. Total same-store adjusted NOI rose 3.6%. Healthpeak earned $0.02 a diluted share, compared with a loss of $0.17 a year earlier. Nareit FFO was $0.43 a share and FFO as adjusted was $0.44, down from $0.45 and $0.46. Revenue rose to $820.9 million from $705.9 million. The company raised its 2026 FFO as adjusted guidance to $1.76 to $1.78 a share, from $1.73 to $1.77 in August, a 2-cent increase at the midpoint. It lifted its forecast for total same-store cash NOI growth to 0.5% to 2.0%, from 0% to 1.5%. Earnings-per-share guidance fell to $0.39 to $0.41 from $0.48 to $0.52, which the company attributed to depreciation and amortization from Janus Living's senior housing acquisitions. Healthpeak said that change does not affect FFO as adjusted. Healthpeak also entered into a new $500 million unsecured delayed-draw term loan in October, priced at SOFR plus 80 basis points and maturing in October 2030. The loan was undrawn at closing. Net debt was 4.7 times adjusted EBITDAre, and liquidity was $3.8 billion as of Oct. 30. The monthly dividend is $0.10167 a share, or $1.22 annualized. After quarter-end, Healthpeak said 643,000 square feet of lab space and 1.3 million square feet of outpatient space were executed or under letter of intent after quarter-end. In August, the company raised guidance on a 19.2% senior housing gain, and Janus Living has since expanded its revolving credit line to $1.25 billion to keep buying. More REIT coverage is in RealtyWire's commercial real estate section.